ZNF713

Summary

ZNF713 (zinc finger protein 713, HGNC:22043) is a protein-coding gene on chromosome 7p11.2, encoding Zinc finger protein 713 (Q8N859). May be involved in transcriptional regulation.

The protein encoded by this gene contains C2H2 zinc finger domains. In some individuals, a CGG-repeat expansion from 5-22 repeats to 68-450 repeats has been identified in the first intron of this gene. This mutation is thought to effect the expression of this gene and it has been proposed that it may be associated with Autistic Spectrum Disorder.

Source: NCBI Gene 349075 — RefSeq curated summary.

At a glance

• Gene–disease (curated): autism (Limited, GenCC)
• GWAS associations: 8
• Clinical variants (ClinVar): 40 total
• MANE Select transcript: NM_182633

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:22043
Approved symbol	ZNF713
Name	zinc finger protein 713
Location	7p11.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ39963
Ensembl gene	ENSG00000178665
Ensembl biotype	protein_coding
OMIM	616181
Entrez	349075

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 2 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000411863, ENST00000429591, ENST00000466630, ENST00000482436, ENST00000484120, ENST00000633730

RefSeq mRNA: 2 — MANE Select: NM_182633 NM_001366796, NM_182633

CCDS: CCDS34639, CCDS94106

Canonical transcript exons

ENST00000429591 — 7 exons

Exon	Start	End
ENSE00001635728	55938982	55942225
ENSE00003550248	55923162	55923288
ENSE00003551826	55923607	55923699
ENSE00003633109	55906253	55906379
ENSE00003634851	55911616	55912068
ENSE00003647668	55912635	55912723
ENSE00003782317	55887456	55887680

Expression profiles

Bgee: expression breadth ubiquitous, 188 present calls, max score 82.15.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.5583 / max 108.5483, expressed in 1103 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
78761	2.5583	1103

Top tissues by expression

242 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	82.15	gold quality
ganglionic eminence	UBERON:0004023	80.90	gold quality
ventricular zone	UBERON:0003053	80.78	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.20	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.39	gold quality
corpus callosum	UBERON:0002336	76.68	gold quality
monocyte	CL:0000576	71.32	gold quality
leukocyte	CL:0000738	70.98	gold quality
prefrontal cortex	UBERON:0000451	70.95	gold quality
calcaneal tendon	UBERON:0003701	70.81	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	70.65	gold quality
smooth muscle tissue	UBERON:0001135	70.61	gold quality
islet of Langerhans	UBERON:0000006	70.50	gold quality
sural nerve	UBERON:0015488	70.45	gold quality
hindlimb stylopod muscle	UBERON:0004252	70.03	gold quality
spinal cord	UBERON:0002240	69.55	gold quality
colonic epithelium	UBERON:0000397	69.49	gold quality
stromal cell of endometrium	CL:0002255	69.45	gold quality
adrenal tissue	UBERON:0018303	69.42	gold quality
right uterine tube	UBERON:0001302	69.11	gold quality
bone marrow cell	CL:0002092	68.47	silver quality
bronchial epithelial cell	CL:0002328	67.93	gold quality
bronchus	UBERON:0002185	66.68	gold quality
muscle of leg	UBERON:0001383	66.22	gold quality
gall bladder	UBERON:0002110	65.69	gold quality
amygdala	UBERON:0001876	65.56	gold quality
pituitary gland	UBERON:0000007	65.50	gold quality
gastrocnemius	UBERON:0001388	65.34	gold quality
pancreas	UBERON:0001264	65.17	gold quality
inferior vagus X ganglion	UBERON:0005363	65.15	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	6.39

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): STAT1

miRNA regulators (miRDB)

87 targeting ZNF713, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-579-3P	99.86	71.66	3628

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	A430033K04Rik	ENSMUSG00000056014

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631)

Protein

Protein identifiers

Zinc finger protein 713 — Q8N859 (reviewed: Q8N859)

All UniProt accessions (3): A0A8I5JYA4, Q8N859, F8WD84

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Tissue specificity. Expressed in fetal and adult brain.

Disease relevance. A 7p11.2 folate-sensitive fragile site, FRA7A, has been identified in 2 unrelated families diagnosed with an autistic disorder. FRA7A is associated with a CGG-repeat expansion in a ZNF713 5’-intron. In the first family, the expanded allele contained about 450 CGG-repeats. It showed hypermethylation and reduced ZNF713 expression. In the second family, 3 autistic siblings exhibited a heterozygous expansion of about 70 repeats, corresponding to premutations, which were partially or mosaically methylated. Mitotic instability of the premutation was observed in one affected sibling. In this family, ZNF713 tends to be up-regulated. It has been suggested that ZNF713 misregulation in the brain might be involved in the pathogenicity of autistic disorder.

Polymorphism. The ZNF713 gene contains a polymorphic CGG-repeat expansion in the non-coding region: 5 to 22 repeats are found in the normal population, most frequently 7. Higher numbers of repeats (50-200 CGG) are considered as premutations, which may affect methylation and cause mitotic instability.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (2): NP_001353725, NP_872439* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050758	Znf_C2H2-type	Family

Pfam: PF00096, PF01352, PF13465

UniProt features (12 total): zinc finger region 6, compositionally biased region 2, region of interest 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N859-F1	55.50	0.11

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 43 (showing top): GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, HOXB4_TARGET_GENES, LHX9_TARGET_GENES, ZNF513_TARGET_GENES, MIR371B_5P, MIR12136, MIR340_5P, MIR5582_3P, MIR548AR_3P, MIR548AW, MIR579_3P, MIR664B_3P, MIR186_5P, MIR548F_3P

GO Biological Process (2): regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (6): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

630 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF713	SUMF2	Q8NBJ7	651
ZNF713	NIPSNAP2	O75323	573
ZNF713	SEPTIN14	Q6ZU15	507
ZNF713	PHKG1	Q16816	495
ZNF713	ZNF385B	Q569K4	480
ZNF713	ZNF827	Q17R98	471
ZNF713	MRPS17	Q9Y2R5	470
ZNF713	DIP2B	Q9P265	456
ZNF713	CCT6A	P40227	455
ZNF713	CHCHD2	Q9Y6H1	443
ZNF713	SEC61G	P38384	431
ZNF713	TSHZ3	Q63HK5	430
ZNF713	OR5H14	A6NHG9	414
ZNF713	PRSS53	Q2L4Q9	413
ZNF713	PSPH	P78330	410

IntAct

3 interactions, top by confidence:

A	B	Type	Score
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
ZNF713	SERPINB8	psi-mi:“MI:0914”(association)	0.350

BioGRID (7): ZNF713 (Affinity Capture-RNA), ZNF713 (Synthetic Lethality), SERPINB8 (Affinity Capture-MS), NEDD8-MDP1 (Affinity Capture-MS), SORL1 (Affinity Capture-MS), ZNF713 (Affinity Capture-MS), ZNF713 (Affinity Capture-MS)

ESM2 similar proteins: A0JPL0, A3KN36, A7MBI1, A8MT65, B2RXC5, D3ZVT0, P08042, P21506, P51508, P52738, Q02525, Q06730, Q12901, Q2KI58, Q2M218, Q2M3W8, Q2M3X9, Q2VY69, Q49AA0, Q4R6J4, Q4V8A8, Q5FWF6, Q5HY98, Q5RB33, Q5RC79, Q5REF1, Q5T5D7, Q5VIY5, Q61967, Q6P2D0, Q6ZN11, Q86XU0, Q86Y25, Q8N782, Q8N859, Q8NB42, Q8TF39, Q8TF47, Q8WXB4, Q95K49

Diamond homologs: A0A1W2PQL4, A6NK75, A6NN14, A6NNF4, A6NP11, A8MQ14, A8MTY0, A8MUV8, A8MXY4, B4DX44, B4DXR9, E9PYI1, O14628, O43345, O75290, O75346, O75373, O75437, O95780, P0CB33, P0DKX0, P0DPD5, P16373, P17019, P17038, P21506, P35789, P52736, P52738, P52744, Q03923, Q03924, Q03936, Q03938, Q05481, Q14586, Q14593, Q14929, Q15928, Q3KNS6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

40 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	37
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1804 predictions. Top by Δscore:

Variant	Effect	Δscore
7:55887677:GGAG:G	donor_gain	1.0000
7:55887678:GAG:G	donor_gain	1.0000
7:55887678:GAGG:G	donor_gain	1.0000
7:55887679:AGG:A	donor_loss	1.0000
7:55887679:AGGT:A	donor_loss	1.0000
7:55887681:G:A	donor_loss	1.0000
7:55887681:G:GG	donor_gain	1.0000
7:55887681:GT:G	donor_loss	1.0000
7:55887682:T:G	donor_loss	1.0000
7:55912633:A:AG	acceptor_gain	1.0000
7:55912634:G:GA	acceptor_gain	1.0000
7:55912634:GTT:G	acceptor_gain	1.0000
7:55912634:GTTA:G	acceptor_gain	1.0000
7:55912634:GTTAT:G	acceptor_gain	1.0000
7:55912721:CAGG:C	donor_loss	1.0000
7:55912722:AGGT:A	donor_loss	1.0000
7:55912723:GGTA:G	donor_loss	1.0000
7:55912724:G:GG	donor_gain	1.0000
7:55912724:GTAA:G	donor_loss	1.0000
7:55912725:T:A	donor_loss	1.0000
7:55923315:G:GT	donor_gain	1.0000
7:55887679:AG:A	donor_gain	0.9900
7:55887680:GG:G	donor_gain	0.9900
7:55912630:CCTA:C	acceptor_loss	0.9900
7:55912630:CCTAG:C	acceptor_gain	0.9900
7:55912631:CTA:C	acceptor_loss	0.9900
7:55912632:TA:T	acceptor_loss	0.9900
7:55912633:A:AC	acceptor_loss	0.9900
7:55912633:A:T	acceptor_loss	0.9900
7:55923272:G:GT	donor_gain	0.9900

AlphaMissense

2985 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:55939725:T:C	F338L	0.999
7:55939727:T:A	F338L	0.999
7:55939727:T:G	F338L	0.999
7:55939809:T:C	F366L	0.999
7:55939811:C:A	F366L	0.999
7:55939811:C:G	F366L	0.999
7:55939893:T:C	F394L	0.999
7:55939895:T:A	F394L	0.999
7:55939895:T:G	F394L	0.999
7:55939641:T:C	F310L	0.998
7:55939643:C:A	F310L	0.998
7:55939643:C:G	F310L	0.998
7:55939732:G:C	R340P	0.998
7:55939744:T:C	L344P	0.998
7:55939557:T:C	F282L	0.997
7:55939559:C:A	F282L	0.997
7:55939559:C:G	F282L	0.997
7:55939810:T:C	F366S	0.997
7:55939828:T:C	L372P	0.997
7:55939838:T:A	H375Q	0.997
7:55939838:T:G	H375Q	0.997
7:55939894:T:C	F394S	0.997
7:55923243:T:G	Y44D	0.996
7:55923277:T:C	L55P	0.996
7:55939670:T:A	H319Q	0.996
7:55939670:T:G	H319Q	0.996
7:55939754:T:A	H347Q	0.996
7:55939754:T:G	H347Q	0.996
7:55939760:A:C	R349S	0.996
7:55939760:A:T	R349S	0.996

dbSNP variants (sampled 300 via entrez): RS1000105760 (7:55889481 A>G), RS1000164409 (7:55920320 A>C,G), RS1000183518 (7:55932389 G>A,C), RS1000235879 (7:55932048 G>C), RS1000327333 (7:55906734 G>T), RS1000469524 (7:55926415 T>A,C), RS1000493081 (7:55921813 T>G), RS1000506995 (7:55919735 A>G), RS1000607123 (7:55913270 C>T), RS1000641533 (7:55915220 A>C,G,T), RS1000645980 (7:55889722 T>C), RS1000712668 (7:55913636 G>A), RS1000777685 (7:55925995 G>A), RS1000892874 (7:55901674 A>G), RS1000959303 (7:55893983 G>A)

Disease associations

OMIM: gene MIM:616181 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
autism	Limited	Autosomal dominant

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST005998_16	Alanine transaminase levels	4.000000e-09
GCST007382_27	Plasma free amino acid levels (adjusted for twenty other PFAAs)	1.000000e-22
GCST007385_30	Plasma free amino acid levels	1.000000e-19
GCST007876_103	Estimated glomerular filtration rate	1.000000e-08
GCST008839_384	Height	9.000000e-17
GCST010118_148	Type 2 diabetes	4.000000e-08
GCST012251_16	Macular telangiectasia type 2	3.000000e-07
GCST012252_7	Macular telangiectasia type 2	6.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005134	amino acid measurement
EFO:0009774	serine measurement
EFO:1002009	macular telangiectasia type 2

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, decreases expression	2
Arsenic	increases abundance, affects methylation, decreases expression	2
Valproic Acid	affects expression, decreases expression	2
bisphenol F	affects cotreatment, increases expression	1
TAK-243	increases sumoylation	1
bisphenol A	affects cotreatment, increases expression	1
beta-lapachone	decreases expression	1
pentanal	decreases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	decreases expression	1
Sunitinib	decreases expression	1
Vorinostat	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Malathion	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
1-Methyl-3-isobutylxanthine	increases expression, affects cotreatment	1
Cadmium Chloride	decreases expression, increases expression	1
Okadaic Acid	increases expression	1

Cellosaurus cell lines

3 cell lines: 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A8K0	SEES3-1V human ZNF713, clone1	Embryonic stem cell	Male
CVCL_A8K1	SEES3-1V human ZNF713, clone2	Embryonic stem cell	Male
CVCL_A8K2	SEES3-1V human ZNF713, clone3	Embryonic stem cell	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms